FDMT Stock Analysis: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$11.71
1.29 (12.38%)
▲
5d:
+27.01%
30d:
+34.75%
90d:
+26.87%
WAIT
LOW Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: FDMT is 19.9% above its trading range ($9.77). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: FDMT is 19.9% above its trading range ($9.77). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $11.71, which is considered extended relative to its 30-day fair value range of $8.52 to $9.77.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $10.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.4% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $10.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.4% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.52 -
$9.77
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+19.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.4%)
- BULLISH: Trading 170.8% below Wall St target ($28.22)
- WARNING: Recommendation downgraded due to 19.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$8.52 -
$9.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.37
Resistance Level
$10.66
Current Trend
Sideways
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.80
Wall Street Target
$28.22
(+170.8%)
Revenue Growth (YoY)
21664.3%
Profit Margin
-182.3%
Share & Embed Analysis
Last updated: June 23, 2026 12:56 PM ET
Data refreshes hourly during market hours. Next update: 1:56 PM
Data refreshes hourly during market hours. Next update: 1:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashoo Gupta
SELL
390 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
